Transcatheter valve‐in‐valve for failing bioprosthetic aortic valve: Usually a good idea

Key Points Use of bioprosthetic implants for surgical aortic valve replacements (SAVR) has been increasing in the recent years Surgical redo AVRs for failed surgical aortic bioprostheses have been traditionally considered the standard practice; however, in patients with higher surgical risk scores, transcatheter valve‐in‐valve aortic valve replacements are being commonly performed There is scarcity of data comparing these two approaches in this complex patient cohort Available data suggest that transcatheter ViV aortic valve replacement is generally a safe approach once some caveats are accounted for